Cencora stock sets specialty-led path for fiscal 2027

Cencora reported its fiscal fourth-quarter and full-year results on Wednesday, November 4, 2026, after the fiscal year ended September 30. The pharmaceutical solutions company posted stronger adjusted earnings and set out a fiscal 2027 plan that gives specialty services a larger strategic role. The results and outlook were published in the company's investor release.

Stronger quarter, broader earnings base

Revenue rose 5.5 percent from the prior-year quarter to 88.4 billion US dollars. GAAP diluted earnings per share improved to 2.71 US dollars from a loss of 1.75 US dollars, while adjusted diluted earnings per share increased 21.4 percent to 4.66 US dollars from 3.84 US dollars.

Adjusted operating income climbed 22.1 percent to 1.2 billion US dollars. Cencora attributed the improvement in part to higher gross profit and the February 2026 acquisition of OneOncology. The company also said increased sales of specialty products and products in the GLP-1 class supported revenue, although lower-margin GLP-1 sales weighed partly on gross margin.

For the full fiscal year, revenue increased 5.0 percent to 337.4 billion US dollars. Adjusted diluted earnings per share rose 12.3 percent to 17.97 US dollars. Reported results also included material items, including a gain tied to the OneOncology transaction, acquisition-related costs, restructuring expenses, litigation-related items and a LIFO credit, making the adjusted figures the clearer measure of underlying operating performance.

Specialty services lead the outlook

Cencora reorganized its reporting structure for fiscal 2027 around Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. Management expects group revenue to grow 3 percent to 5 percent and adjusted operating income to increase 4 percent to 6 percent.

The specialty division is expected to be the faster-growing part of the business. Its revenue outlook calls for growth of 9 percent to 14 percent, compared with 4 percent to 6 percent for Pharmaceutical Distribution and Services. The corresponding adjusted operating income ranges are 18 percent to 21 percent for specialty and 2 percent to 4 percent for distribution.

Cencora forecasts fiscal 2027 adjusted diluted earnings per share of 19.40 to 19.75 US dollars, implying growth of 8 percent to 10 percent from fiscal 2026. It expects adjusted free cash flow of approximately 3.5 billion US dollars and capital expenditure of approximately 1.0 billion US dollars. The company reaffirmed longer-term targets of 7 percent to 10 percent adjusted operating income growth and 10 percent to 14 percent adjusted diluted EPS growth.

Dividend adds shareholder support

The board declared a quarterly dividend of 0.66 US dollars per common share on November 3, a 10 percent increase from 0.60 US dollars. The payment is scheduled for November 30 to shareholders of record at the close of business on November 13.

Management also highlighted the acquisition of OneOncology and a planned acquisition of American Oncology Network, while Cencora expects the sale of its stake in Profarma to close in the first fiscal quarter. These portfolio moves make the new specialty reporting line an important focus for investors assessing whether the higher-growth mix can offset the lower margins typical of large-scale distribution.

Cencora stock traded at 316.10 euros on Lang & Schwarz at 12:39 CET on Friday, November 13, 2026.

The S&P 500 provides the broader market backdrop for US-listed healthcare shares.

Further company-specific coverage is available in more news and analyses on Cencora stock.